Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova...(an organisation that is highly efficient...),Health

Date:9/8/2009

an organisation that is highly efficient with its resources. To be cost-competitive, the recipient has made efforts to bring about improvements in manufacturing efficiencies by impressive growth in sales, increased margins, better return on assets (ROA), and effective debt-equity management, adding value for investors.

Frost & Sullivan Best Practices Awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research in order to identify best practices in the industry.

About Pronova BioPharma ASA

Pronova BioPharma is a global leader in the research, development and manufacture of marine-originated omega-3 derived pharmaceutical products. Pronova BioPharma's first commercialized product is branded as Omacor((R)) in a number of countries throughout Europe and Asia and as Lovaza((TM)) in the United States. The product is manufactured at the Company's plant in Sandefjord, Norway using a unique and complex process. An additional manufacturing plant is under construction in Kalundborg, Denmark and is expected to be operational in first quarter 2010.

Omacor/Lovaza is the first and only EU- and FDA-approved omega-3 derived prescription drug. The drug is prescribed as an adjunct to diet for the treatment of elevated levels of triglycerides in humans, a condition known as hypertriglyceridemia (HTG), a form of dyslipidemia (or disorder of lipid metabolism). Very high triglycerides have been linked to a number of cardiovascular diseases. Omacor is also approved in key European and certain Asian markets for the secondary prevention of post-myocardial infarction, or Post-MI
'/>"/>

SOURCE Frost & Sullivan Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Aging Population, Heightened Consumer Awareness Propel U.S. Bone and Joint Health Ingredients, Says Frost & Sullivan
2. Added Investment Into Healthcare By the Government Drives Growth in the European Hospital Information Systems Market, Notes Frost & Sullivan
3. U.S. Compression Therapy Market to Reach $1.16 Billion in 2015, Finds Frost & Sullivan
4. Frost & Sullivan Recognizes Carestream Health with the 2009 Latin American Computed Radiology Customer Value Leadership Award
5. Mennen Medical Receives Frost & Sullivan 2009 European Patient Monitoring Technology Leadership Award
6. Frost & Sullivan: Growing Healthcare Tourism in Malaysia
7. A Wound that Does Not Heal: Frost & Sullivan Reveals the Impact of Chronic Ulcers on the European Healthcare System
8. Frost & Sullivan: Malaysia Diagnostics and Devices Industry Outlook 2009
9. Frost & Sullivan: Medico Legal Implications Related to the Usage of Electronic Health Record
10. Smart Payment Strategies Enable Growth in Home Health Care and Disease Management Markets for Remote Patient Monitoring, Finds Frost & Sullivan
11. Frost & Sullivan: Outsourcing/Offshoring Environment Possesses Considerable Potential for Pharmacovigilance Market